Allogenic and Autologous Anti-CD7 CAR-T-cell Therapies in Relapsed or Refractory T-cell Malignancies

2023.04.25

Blood Cancer J

Publication Brief

Comparative analysis of allogeneic versus autologous anti-CD7 CAR-T therapies in r/r T-cell malignancies, evaluating efficacy, persistence, and safety profiles.

Abstract

Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retention have shown efficacy in patients with T-cell acute lymphoblastic leukemia (ALL). Here we launched a phase I trial to explore differences between autologous and allogeneic anti-CD7 CAR-T therapies in T-cell ALL and lymphoma. Ten patients were treated and 5 received autologous CAR-T therapies. No dose-limiting toxicity or neurotoxicity was observed. Grade 1-2 cytokine release syndrome occurred in 7 patients, and grade 3 in 1 patient. Grade 1-2 graft-versus-host diseases were observed in 2 patients. Seven patients had bone marrow infiltration, and 100% of them achieved complete remission with negative minimal residual disease within one month. Two-fifths of patients achieved extramedullary or extranodular remission. The median follow-up was 6 (range, 2.7-14) months and bridging transplantation was not administrated. Patients treated with allogeneic CAR-T cells had higher remission rate, less recurrence and more durable CAR-T survival than those receiving autologous products. Allogeneic CAR-T cells appeared to be a better option for patients with T-cell malignancies.

Fig. 2: Clinical response to anti-CD7 CAR-T cells.

Journal: Blood Cancer J. 2023 Apr 25.

Volume / Pages: 13(1):61

DOI: 10.1038/s41408-023-00822-w

PubMed: PubMed: 37095094

Allogenic and Autologous Anti-CD7 CAR-T-cell Therapies in Relapsed or Refractory T-cell Malignancies

Publication Brief

Abstract

Related Picks

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia

Donor-derived CD7 CAR-T Cells for Pediatric and Adult Relapsed/Refractory T-ALL/LBL

BCMA/GPRC5D Bispecific CAR T-cell Therapy for R/R Multiple Myeloma with Extramedullary Disease

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Anti-GPRC5D CAR T-cell Therapy as Salvage Treatment in Patients with Progressive Multiple Myeloma after Anti-BCMA CAR T-cell Therapy

Prominent Efficacy and Good Safety of Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia

Phase I trial validating a simplified autologous CD7 CAR-T manufacturing process without T-cell pre-selection, expanding accessibility for pediatric r/r T-ALL patients

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

Sequential CD19 and CD22 Chimeric Antigen Receptor T-cell Therapy for Childhood Refractory or Relapsed B-cell Acute Lymphocytic Leukaemia

Long-term Follow-up of Donor-derived CD7 CAR T-cell Therapy in T-cell Acute Lymphoblastic Leukemia

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Pre-transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy followed by Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia

CD22 CAR T-cell Therapy in Refractory or Relapsed B Acute Lymphoblastic Leukemia

High Efficacy and Safety of Low Dose CD19-directed CAR-T-cell Therapy in 51 Refractory or Relapsed B Acute Lymphoblastic Leukemia Patients

A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer